<DOC>
	<DOCNO>NCT00000143</DOCNO>
	<brief_summary>To compare new CMV retinitis drug , cidofovir , regimen ganciclovir intraocular device plus oral ganciclovir respect efficacy prevent vision loss . To compare treatment regimen incorporate highly active local therapy ( ganciclovir device ) treatment regimen .</brief_summary>
	<brief_title>Studies Ocular Complications AIDS ( SOCA ) -- Ganciclovir-Cidofovir CMV Retinitis Trial ( GCCRT )</brief_title>
	<detailed_description>Cytomegalovirus ( CMV ) among frequently encounter opportunistic infection patient AIDS . In era prophylaxis pneumocystic pneumonia , CMV disease estimate affect 45 percent patient AIDS sometime diagnosis AIDS death . Retinitis estimate account 85 percent CMV disease patient , make CMV retinitis common ocular infection encounter . CMV retinitis relatively late-stage manifestation , associate cluster differentiation 4 ( CD4 ) + T-cell count &lt; 100 cells/µL often &lt; 50 cells/µL . All currently available treatment CMV suppress viral replication eliminate virus body . Discontinuation therapy associate prompt relapse retinitis . Despite use chronic suppressive therapy , relapse retinitis generally occur , least systemically administer anti-CMV drug . The first two treatment approve CMV retinitis intravenous ganciclovir intravenous foscarnet . Both give daily intravenous infusion therefore require central venous catheter . The development newer treatment focus efficacious treatment , also treatments require central venous catheter . Available treatment include oral ganciclovir , ganciclovir intraocular device , intravenous cidofovir . In vitro data suggest combination therapy synergistic inhibit viral replication ; therapy include foscarnet-ganciclovir combination cidofovir-ganciclovir combination . In SOCA -- CMV Retinitis Retreatment Trial , combination intravenous ganciclovir foscarnet effective either drug alone treatment relapsed retinitis . Therefore , combination intermittent intravenous cidofovir daily oral ganciclovir may attractive therapy relapsed disease may provide synergy control ocular visceral disease necessitate either central venous catheter intraocular surgical procedure . The Ganciclovir-Cidofovir CMV Retinitis Trial ( GCCRT ) randomize , multicenter clinical trial . Patients assign receive one two regimen : ( 1 ) ganciclovir intraocular device plus oral ganciclovir ( 2 ) intravenous cidofovir . The intraocular device surgically implanted baseline every 6 8 month eye CMV retinitis . Oral ganciclovir take dose 1 gram three time daily . Cidofovir administer intravenously 5 mg/kg weekly 2 consecutive week every 2 week thereafter . If disease progression occur patient receive cidofovir , patient give reinduction therapy , oral ganciclovir dose 1 gram three time per day add treatment . If patient assign cidofovir unable tolerate regimen , alternative systemic regimen recommend . Study outcome variable include decrease three line baseline best correct visual acuity rate visual field loss . The study also assess variable include mortality , blood CMV HIV load , quality life , medical cost . Treatment assignment mask either patient clinician ; however , read fundus photographs determine change retinal involvement progression mask .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion criterion : Age 13 year old Diagnosis AIDS accord current Centers Disease Control Prevention ( CDC ) definition Diagnosis active CMV retinitis SOCAcertified ophthalmologist ( involvement zone amount retina allow ) Best correct visual acuity 20/100 good least one eye At least one lesion 750 cells/µL great Platelet count 50,000 cells/µL great Willingness ability , assistance caregiver necessary comply treatment follow procedure Willingness men woman childbearing potential practice adequate birth control prevent pregnancy study 3 month afterwards Collection baseline data within 5 day prior randomization Signed consent statement Exclusion criterion : Media opacity preclude visualization fundus otherwise eligible eye Treatment CMV retinitis ganciclovir intraocular implant within 9 month study entry Medical problem drug alcohol abuse sufficient hinder adherence treatment follow procedure Unwillingness refrain breastfeed study 3 month afterwards</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>